CN103124785A - 在急性护理背景中使用脂蛋白相关磷脂酶a2的方法 - Google Patents

在急性护理背景中使用脂蛋白相关磷脂酶a2的方法 Download PDF

Info

Publication number
CN103124785A
CN103124785A CN2011800326354A CN201180032635A CN103124785A CN 103124785 A CN103124785 A CN 103124785A CN 2011800326354 A CN2011800326354 A CN 2011800326354A CN 201180032635 A CN201180032635 A CN 201180032635A CN 103124785 A CN103124785 A CN 103124785A
Authority
CN
China
Prior art keywords
pla2
stroke
patients
tia
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800326354A
Other languages
English (en)
Chinese (zh)
Inventor
乔安·蒙塔内尔
马里亚·皮拉尔·德尔加多马蒂内兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Diadexus Inc
Original Assignee
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Diadexus Inc filed Critical Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Publication of CN103124785A publication Critical patent/CN103124785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A61B5/02014—Determining aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0891—Clinical applications for diagnosis of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/488—Diagnostic techniques involving Doppler signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
CN2011800326354A 2010-04-30 2011-05-02 在急性护理背景中使用脂蛋白相关磷脂酶a2的方法 Pending CN103124785A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33019310P 2010-04-30 2010-04-30
US61/330,193 2010-04-30
PCT/US2011/034728 WO2011137419A1 (en) 2010-04-30 2011-05-02 Methods using lipoprotein-associated phospholipase a2 in an acute care setting

Publications (1)

Publication Number Publication Date
CN103124785A true CN103124785A (zh) 2013-05-29

Family

ID=44861949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800326354A Pending CN103124785A (zh) 2010-04-30 2011-05-02 在急性护理背景中使用脂蛋白相关磷脂酶a2的方法

Country Status (6)

Country Link
US (1) US20130236450A1 (enExample)
EP (1) EP2563914A4 (enExample)
JP (1) JP2013527772A (enExample)
CN (1) CN103124785A (enExample)
CA (1) CA2798122A1 (enExample)
WO (1) WO2011137419A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US20160349271A1 (en) * 2014-02-14 2016-12-01 Diadexus, Inc. Biomarkers for cardiovascular disease
KR101629560B1 (ko) * 2014-07-30 2016-06-13 경희대학교 산학협력단 부작용이 억제된 암치료용 약학 조성물
US10900063B2 (en) 2016-06-22 2021-01-26 Asahi Kasei Pharma Corporation Measurement of Lp-PLA2 activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
US20070077614A1 (en) * 2003-04-01 2007-04-05 Wolfert Robert L Uses of lp-pla2 in combination to assess coronary risk
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077614A1 (en) * 2003-04-01 2007-04-05 Wolfert Robert L Uses of lp-pla2 in combination to assess coronary risk
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MONTANER,JOAN: "Blood biomarkers to guide stroke thrombolysis", 《FRONTIERS IN BIOSCIENCE》 *
PHILIP B. GORELICK: "Lipoprotein-Associated Phospholipase A2 and Risk of Stroke", 《THE AMERICAN JOURNAL OF CARDIOLOGY》 *

Also Published As

Publication number Publication date
EP2563914A4 (en) 2013-11-20
US20130236450A1 (en) 2013-09-12
CA2798122A1 (en) 2011-11-03
WO2011137419A1 (en) 2011-11-03
WO2011137419A8 (en) 2012-11-29
EP2563914A1 (en) 2013-03-06
JP2013527772A (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
Eder et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study.
Kjaergaard et al. Elevated plasma YKL‐40 levels and ischemic stroke in the general population
Papa et al. Increased carotid intima–media thickness in patients with inflammatory bowel disease
Cheng et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease
Wang et al. Increased Serum Level of Growth Differentiation Factor 15 (GDF‐15) is Associated with Coronary Artery Disease
Li et al. Increased serum cathepsin K in patients with coronary artery disease
Gluba-Brzózka et al. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
Piñón et al. Inflammation, Atherosclerosis, and cardiovascular disease risk: PAPP-A, Lp-PLA2, and cystatin C. New insights or redundant information?
Li et al. Reduced activity of HDAC3 and increased acetylation of histones H3 in peripheral blood mononuclear cells of patients with rheumatoid arthritis
Hallstrand et al. Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity
US20130236450A1 (en) Methods Using Lipoprotein-Associated Phospholipase A2 in an Acute Care Setting
Kaski et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome
Gorog et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the “Japanese paradox”
Liao et al. BRAP activates inflammatory cascades and increases the risk for carotid atherosclerosis
Csecsei et al. Relationship between cardiac troponin and thrombo-inflammatory molecules in prediction of outcome after acute ischemic stroke
Avci et al. The prognostic utility of plasma NGAL levels in ST segment elevation in myocardial infarction patients
Miura et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease
Samnegård et al. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients
Massot et al. Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease
Tsukimura et al. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
Khakpour et al. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy
Maksimovic et al. Relationship between peripheral arterial disease and metabolic syndrome
Bjerre et al. Micro‐and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients—An exploratory study
Kohashi et al. Effect of smoking status on monocyte tissue factor activity, carotid atherosclerosis and long-term prognosis in metabolic syndrome
Gensini et al. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130529